BASEL, Switzerland, Feb. 25, 2026 /PRNewswire/ -- Melodia Therapeutics AG today announced that the United States Patent and Trademark Office (USPTO) has granted a key U.S. patent covering a structurally novel DPP1 (Cathepsin C) inhibitor, currently developed as MLD-151 by Melodia Therapeutics and discovered by its partner, Alivexis, Inc., strengthening the intellectual property foundation supporting Melodia's lead development program. The newly issued patent (U.S. Patent No. 12,522,593; Internat

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 inf

GSK said it will acquire a 100% equity stake in Canadian clinical-stage biotech 35Pharma for $950 million in cash, securing rights to the latter's lead asset — an activin signalling inhibitor (ASI) being developed for pulmonary hypertension (PH). "We're delighted to add HS235 to our pipeline, a potential best-in-class medicine with a differentiated profile to reduce risk of bleeding and provide potential metabolic benefits clinically relevant to PH patients," said Tony Wood, chief scientific of

February 24, 2026 – Jnana Therapeutics,a clinical-stage biotechnology company leveraging its next-generation RAPID chemoproteomics platform, announces the achievement of a second pre-clinical milestone from its first collaboration agreement with Roche (SIX:RO, ROG; OTCQX: RHHBY).Jnana has advanced a Roche-partnered immune program to an additional pre-clinical milestone, triggering a milestone payment to Jnana and handover to Roche. This is a first-in-class small molecule that uniquely inhibits a

February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 6 million to Basilea to continue the development of Basilea’s novel

Ontario's FAST program aims to speed up access to breakthrough cancer drugs for patients by almost a full year sooner.1 Itovebi offers a targeted treatment for advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation, following recurrence on or after completing adjuvant endocrine treatment. This mutation is found in approximately 40 per cent of HR-positive breast cancers and is generally associated with poor outcomes.2,3,4 Feb. 24, 2026 - Hoffmann-La Roche Limited (Roche Canada

Feb. 23, 2026 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate imm

Bristol Myers Squibb (NYSE: BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in adults with Alpha (α)-Thalassemia. The non‑transfusion‑dependent (NTD) and transfusion‑dependent (TD) cohorts of the study met their respective primary endpoints, with Reblozyl demonstrating a statistically significant and clinically meaningful increase in hemoglobin levels in NTD patie

First patient dosed in Phase 1b randomized, placebo-controlled study evaluating safety, tolerability and weight loss over 12 weeks Market research indicates strong demand for ketogenic-metabolic approaches, including among adults with obesity who are not currently receiving treatment BL-001 positioned as a potential oral ketogenic-metabolic therapy designed for gradual, sustained weight loss with improved tolerability Feb. 24, 2026 -- Bloom Science, Inc., a clinical-stage biotech company focuse

Gilead Sciences has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval. Arcellx partnered with Gilead to develop the BCMA-directed CAR-T anitocabtagene autoleucel (anito-cel) in 2022. Gilead invested in Arcellx as part of the agreement and, having invested again when amending the deal in 2023, owns 11.5% of the company. With Gilead on the hook for $530 million in milestones for anito-cel, analysts had speculated about a pot